Hemogenyx Pharmaceuticals (HEMO) RNS Announcements

Add to Alert list
Date Time Source Announcement
29 Mar 2021 11:05 AM
RNS
Second Price Monitoring Extn
29 Mar 2021 11:00 AM
RNS
Price Monitoring Extension
29 Mar 2021 07:00 AM
RNS
Allotment of Shares
26 Mar 2021 07:00 AM
RNS
Conversion of Convertible Loan Notes
11 Mar 2021 04:41 PM
RNS
Second Price Monitoring Extn
11 Mar 2021 04:36 PM
RNS
Price Monitoring Extension
09 Mar 2021 04:41 PM
RNS
Second Price Monitoring Extn
09 Mar 2021 04:36 PM
RNS
Price Monitoring Extension
09 Mar 2021 02:06 PM
RNS
Second Price Monitoring Extn
09 Mar 2021 02:00 PM
RNS
Price Monitoring Extension
09 Mar 2021 11:00 AM
RNS
Price Monitoring Extension
09 Mar 2021 07:00 AM
RNS
Director/PDMR Shareholding
08 Mar 2021 07:00 AM
RNS
H.C. Wainwright Investment Conference
03 Mar 2021 07:00 AM
RNS
HEMO-CAR-T Update
26 Feb 2021 10:05 AM
RNS
Total Voting Rights
25 Feb 2021 04:56 PM
RNS
Conversion of Convertible Loan Notes
15 Feb 2021 04:41 PM
RNS
Second Price Monitoring Extn
15 Feb 2021 04:36 PM
RNS
Price Monitoring Extension
10 Feb 2021 07:00 AM
RNS
Allotment of Shares
03 Feb 2021 07:01 AM
RNS
Draw Down Under Financing Facility Agreement
29 Jan 2021 02:24 PM
RNS
Publication of Prospectus
13 Jan 2021 07:00 AM
RNS
Update on CDX Antibody Development
06 Jan 2021 03:53 PM
RNS
Result of General Meeting
05 Jan 2021 07:00 AM
RNS
CAR-T Master Translational Agreement with Penn
08 Dec 2020 07:00 AM
RNS
Change to Date of General Meeting
02 Dec 2020 04:41 PM
RNS
Second Price Monitoring Extn
02 Dec 2020 04:36 PM
RNS
Price Monitoring Extension
02 Dec 2020 11:06 AM
RNS
Second Price Monitoring Extn
02 Dec 2020 11:01 AM
RNS
Price Monitoring Extension
02 Dec 2020 07:00 AM
RNS
Posting of Circular
18 Nov 2020 04:41 PM
RNS
Second Price Monitoring Extn
18 Nov 2020 04:36 PM
RNS
Price Monitoring Extension
18 Nov 2020 02:06 PM
RNS
Second Price Monitoring Extn
18 Nov 2020 02:01 PM
RNS
Price Monitoring Extension
18 Nov 2020 10:39 AM
RNS
Financing Facility of up to £60 Million
27 Oct 2020 07:00 AM
RNS
CDX Development Agreement Further Extension
19 Oct 2020 07:00 AM
RNS
Presentation at the American Society of Hematology
06 Oct 2020 07:00 AM
RNS
SAFE-HEMO-CAR-T Effective against AML in vitro
30 Sep 2020 07:00 AM
RNS
Interim Results for the period ended 30 June 2020
22 Sep 2020 12:52 PM
RNS
Further re. Grant of Options
10 Sep 2020 04:40 PM
RNS
Second Price Monitoring Extn
10 Sep 2020 04:35 PM
RNS
Price Monitoring Extension
26 Aug 2020 02:06 PM
RNS
Second Price Monitoring Extn
26 Aug 2020 02:00 PM
RNS
Price Monitoring Extension
25 Aug 2020 04:40 PM
RNS
Second Price Monitoring Extn
25 Aug 2020 04:35 PM
RNS
Price Monitoring Extension
21 Aug 2020 09:52 AM
RNS
Grant of Options
14 Aug 2020 07:00 AM
RNS
Presentations at Cancer Immunotherapy Symposia
11 Aug 2020 07:00 AM
RNS
CAR-T Agreement with University of Pennsylvania
31 Jul 2020 07:00 AM
RNS
Broker's Research Note

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

Hemogenyx Pharmaceuticals PLC is a preclinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases, like leukemia and lymphoma.

Hemo share price launched on LSE at 3p in 2017.

UK 100

Latest directors dealings